Showing 4271-4280 of 7012 results for "".
- Dersimelagon Improves Sunlight Tolerance in EPP and XLPhttps://reachmd.com/news/dersimelagon-improves-sunlight-tolerance-in-epp-and-xlp/2486452/Dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist, significantly improved sunlight tolerance in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), according to Phase 3 INSPIRE trial results presented by Amy Dickey Yeung, MD, at the American Academy of
- Epigenetic Markers May Predict Progesterone Resistance in Endometriosishttps://reachmd.com/news/epigenetic-markers-progesterone-resistance-endometriosis/2486437/Investigators at Yale School of Medicine reported that blood-based DNA methylation patterns might help distinguish subgroups of
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://reachmd.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68
- Zumilokibart Shows Rapid Symptom Relief in Atopic Dermatitishttps://reachmd.com/news/zumilokibart-shows-rapid-symptom-relief-in-atopic-dermatitis/2486425/Zumilokibart (APG777), a half-life–extended anti–IL-13 monoclonal antibody, demonstrated rapid and sustained improvements in symptoms and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to Phase 2 APEX Part A results presented by Emma Guttman-Yassky, MD, PhD,
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://reachmd.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- Facility Volume and Endometrial Cancer: Treatment Patterns and Outcomeshttps://reachmd.com/news/facility-volume-and-endometrial-cancer-treatment-patterns-and-outcomes/2486368/A multicenter retrospective cohort from Emilia-Romagna, Italy, reported in facility volume and endometrial cancer, compared medium-volume centers (11–29 endometrial cancer cases/year) with high-
- Recognition and Management of Mitragynine Pseudoindoxyl Withdrawalhttps://reachmd.com/news/recognition-and-management-of-mitragynine-pseudoindoxyl-withdrawal/2486367/A recent case report describes a hospitalized 44-year-old man with a long polysubstance history who presented with alcohol withdrawal alongside an opioid-type withdrawal syndrome that the authors at
- FDA Approves Restylane Contour for Temple Hollowing Correctionhttps://reachmd.com/news/fda-approves-restylane-contour-for-temple-hollowing-correction/2486354/Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour™ for the correction of temple hollowing in patients aged 21 years and older, expanding its indications beyond cheek augmentation and midface contour deficiencies. The approval enables clinicians to
- National Survey Findings on Obesity Prevalence in High School Studentshttps://reachmd.com/news/survey-obesity-prevalence-high-school/2486310/New Youth Risk Behavior Survey (YRBS) findings show that obesity prevalence among US high school students (grades 9–12) rose
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://reachmd.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot